Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis
Clinical trial NCT07595367 · RECRUITING
Trial details
- NCT number
- NCT07595367
- Sponsor
- Qifeng Zhang
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-10
- Primary completion
- 2028-08-10
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.